{"entity":{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","aka":[],"tldr":"A phase 2 trial of Panobinostat in Hodgkin lymphoma, run by Novartis Pharmaceuticals, completed.","summary":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT00742027 by Novartis Pharmaceuticals, with 129 participants recorded, started 2008-09-16 and reaching its primary completion in 2013-08-12. Interventions recorded: Panobinostat. Conditions recorded: Classical Hodgkin's Lymphoma.\n\nLinked to the drug Panobinostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00742027","url":"https://clinicaltrials.gov/study/NCT00742027"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["panobinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00742027","phase":"2","setting":"A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkins Lymphoma After High-dose Chemotherapy With Autologous Stem Cell Transplant","sponsor":"Novartis Pharmaceuticals","enrolled":129,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00742027/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"drug":[{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/"}]}}